Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | HTR1A | P08908 | 2/20 | 0.60 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.60 |
| ▸ | DRD2 | P14416 | 2/20 | 0.60 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.60 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.60 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.60 |
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | HTR7 | P34969 | 1/20 | 0.50 |
| ▸ | HTR6 | P50406 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL682799 | 0.88 | RXFP1 (0.60) | RAB9AHTR1ACHRM1DRD2ADRA1D | |
| Flufylline SCHEMBL684324 | 0.84 | HTR2A (0.60) | RAB9AHTR1ACHRM1DRD2ADRA1D | |
| SCHEMBL4470996 | 0.80 | ALDH1A1 (0.79) | RXFP1ALDH1A1TSHRMAPK1MAPT | |
| SCHEMBL10896108 | 0.79 | HTR1A (0.50) | RAB9AHTR1ACHRM1DRD2ADRA1D | |
| Perbufylline SCHEMBL682795 | 0.79 | HTR1A (0.61) | RAB9AHTR1ACHRM1DRD2ADRA1D | |
| Fluprofylline SCHEMBL683614 | 0.79 | HTR1A (0.64) | RAB9AHTR1ACHRM1DRD2ADRA1D | |
| SCHEMBL17628698 | 0.78 | RAB9A (0.66) | RAB9ARXFP1TSHRL3MBTL1MAPK1 | |
| SCHEMBL10721910 | 0.78 | HTR1A (0.60) | RAB9AHTR1ACHRM1DRD2ADRA1D | |
| SCHEMBL684335 | 0.78 | LMNA (0.60) | RXFP1ALDH1A1LMNAL3MBTL1MAPK1 | |
| SCHEMBL11155310 | 0.77 | HTR7 (0.74) | RAB9AHTR1ACHRM1DRD2ADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | NGF, DCX, BDNF | RAB9A 2603/4885HTR1A 1265/4885CHRM1 1036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.